M&A menu: India's top 10 drugmakers

SPOTLIGHT: India's top 10 drugmakers
As soon as Ranbaxy's founding Singh family agreed to sell out to Japan's Daiichi Sankyo, the Indian press started speculating about which pharma firm might be next on the buyout list. Well, we can't pretend any knowledge of upcoming M&As, but we can point you to a ranking of subcontinental drugmakers--by revenue--for your own speculative pleasure. Changes are the next target would be among this top 10. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.